The stock of Bio-Path Holdings Inc (NASDAQ: BPTH) has increased by 10.70 when compared to last closing price of 2.71.Despite this, the company has seen a gain of 6.01% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-19 that Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
Is It Worth Investing in Bio-Path Holdings Inc (NASDAQ: BPTH) Right Now?
The stock has a 36-month beta value of 0.36. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BPTH is 1.56M, and at present, short sellers hold a 1.75% of that float. On May 08, 2024, the average trading volume of BPTH was 1.46M shares.
BPTH’s Market Performance
The stock of Bio-Path Holdings Inc (BPTH) has seen a 6.01% increase in the past week, with a -22.88% drop in the past month, and a -67.74% fall in the past quarter. The volatility ratio for the week is 9.98%, and the volatility levels for the past 30 days are at 18.62% for BPTH. The simple moving average for the past 20 days is -1.69% for BPTH’s stock, with a -64.97% simple moving average for the past 200 days.
Analysts’ Opinion of BPTH
Many brokerage firms have already submitted their reports for BPTH stocks, with ROTH Capital repeating the rating for BPTH by listing it as a “Buy.” The predicted price for BPTH in the upcoming period, according to ROTH Capital is $13 based on the research report published on March 11, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BPTH reach a price target of $1.50, previously predicting the price at $4.50. The rating they have provided for BPTH stocks is “Buy” according to the report published on November 13th, 2017.
Maxim Group gave a rating of “Buy” to BPTH, setting the target price at $2 in the report published on August 10th of the previous year.
BPTH Trading at -28.99% from the 50-Day Moving Average
After a stumble in the market that brought BPTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.30% of loss for the given period.
Volatility was left at 18.62%, however, over the last 30 days, the volatility rate increased by 9.98%, as shares sank -21.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.28% lower at present.
During the last 5 trading sessions, BPTH rose by +6.01%, which changed the moving average for the period of 200-days by -87.50% in comparison to the 20-day moving average, which settled at $3.01. In addition, Bio-Path Holdings Inc saw -67.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BPTH
The total capital return value is set at -12.06. Equity return is now at value -220.02, with -167.56 for asset returns.
Based on Bio-Path Holdings Inc (BPTH), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -102.08. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is 833.84.
Currently, EBITDA for the company is -15.66 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
To sum up, Bio-Path Holdings Inc (BPTH) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
